Skip to main content
Journal cover image

87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known

Publication ,  Conference
Tarhini, A; Tan, AC; Naqa, IE; Lee, S; Stephen Hodi, F; Butterfield, L; LaFramboise, W; Storkus, W; Conejo-Garcia, J; Hwu, P; Streicher, H ...
Published in: Journal for ImmunoTherapy of Cancer
November 2021

Duke Scholars

Published In

Journal for ImmunoTherapy of Cancer

DOI

EISSN

2051-1426

Publication Date

November 2021

Volume

9

Issue

Suppl 2

Start / End Page

A95 / A95

Publisher

BMJ

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tarhini, A., Tan, A. C., Naqa, I. E., Lee, S., Stephen Hodi, F., Butterfield, L., … Kirkwood, J. (2021). 87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known. In Journal for ImmunoTherapy of Cancer (Vol. 9, pp. A95–A95). BMJ. https://doi.org/10.1136/jitc-2021-sitc2021.087
Tarhini, Ahmad, Aik Choon Tan, Issam El Naqa, Sandra Lee, F. Stephen Hodi, Lisa Butterfield, William LaFramboise, et al. “87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known.” In Journal for ImmunoTherapy of Cancer, 9:A95–A95. BMJ, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.087.
Tarhini A, Tan AC, Naqa IE, Lee S, Stephen Hodi F, Butterfield L, et al. 87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known. In: Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A95–A95.
Tarhini, Ahmad, et al. “87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, BMJ, 2021, pp. A95–A95. Crossref, doi:10.1136/jitc-2021-sitc2021.087.
Tarhini A, Tan AC, Naqa IE, Lee S, Stephen Hodi F, Butterfield L, LaFramboise W, Storkus W, Conejo-Garcia J, Hwu P, Streicher H, Sondak V, Kirkwood J. 87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known. Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A95–A95.
Journal cover image

Published In

Journal for ImmunoTherapy of Cancer

DOI

EISSN

2051-1426

Publication Date

November 2021

Volume

9

Issue

Suppl 2

Start / End Page

A95 / A95

Publisher

BMJ

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology